International Clinical Psychopharmacology · 2017 · 22 citations · 18 references
PharmacyPharmacokineticsPharmacologyClinical PharmacologyPsychiatric PharmacotherapyPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyIntramuscular Drug DeliveryLong-acting Injectable AntipsychoticsSchizophrenia PharmacotherapyAntipsychotic Long-acting InjectionsAntipsychotic SafetyNegative Syndrome ScalePositive Syndrome ScaleRisperidone PharmacologyRisperidone TherapyStudy PhaseSubcutaneous Drug Administration
This study characterized the pharmacokinetics, safety, and tolerability of Risperidone ISM, a new long-acting intramuscular formulation, for monthly administration without oral supplementation. Patients with schizophrenia received multiple intramuscular injections of 75 mg in the gluteal or deltoid muscle at 28-day intervals. Of the 70 randomized patients, 67 received at least one dose of study medication. The mean Cmax of the active moiety was achieved 24-48 h (tmax) after each administration, regardless of injection site. They ranged over four consecutive doses from 39.6 to 53.2 and 54.1 to 61 ng/ml, when given in gluteal or deltoid muscle, respectively. Active moiety achieved therapeutic levels by 2 h after dose, and the levels were maintained throughout the 4-week dosing period. No significant changes across the study were observed on either Positive and Negative Syndrome Scale or Extrapyramidal Symptoms Scale. Overall, 63 (94%) patients experienced at least one treatment-emergent adverse event (TEAE). One serious TEAE (dystonia) was related to study treatment. The most frequently reported TEAEs were hyperprolactinaemia (57.7%) and injection site pain (32.8%). Risperidone ISM achieved therapeutic levels from the first hours after drug administration and provided a sustained release throughout the 4-week dosing period over multiple intramuscular injections and was found to be safe and well tolerated.
18
An analysis of the time-relations of electrocardiograms
H. C. Bazett · 1920 · 3.8K citations
Medicine, Cardiology, Physiology +10
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
G. M. Simpson, M. B., GH. B. et al. · Acta Psychiatrica Scandinavica · 1970 · 3.3K citations
Medicine, Pharmacology, Psychiatry +10
A Rating Scale for Drug-Induced Akathisia
Thomas R. E. Barnes · The British Journal of Psychiatry · 1989 · 2.2K citations
Medicine, Psychiatry, Psychology +17
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Christoph Hiemke, Pierre Baumann, N. Bergemann et al. · Pharmacopsychiatry · 2011 · 865 citations · Full text
Medicine, Pharmacology, Psychiatry +16